Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Brain Cancer

Brain Cancer

28

Pipeline Programs↗

24

Active Trials↗

18

Companies Involved↗

Brain Cancer is an emerging landscape with 28 programs across 18 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

30/100

Mech. Concentration

12/100

Completion Rate

85/100

Attrition Rate

6/100

Pipeline

Programs by Phase

Preclinical13

Motexafin Gadolinium

Pharmacyclics LLC.

Ergocalciferol

Jazz Pharmaceuticals

Gadolinium

OHSU Knight Cancer Institute

Sulfasalazine

Pfizer

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 16

Nivolumab-Irdye800

Eben Rosenthal

NLG802

Luke, Jason, MD

Ibrutinib

Pharmacyclics LLC.

Ipilimumab

Bristol-Myers Squibb

Indoximod

NewLink Genetics Corporation

Phase 28

Valganciclovir

Engelhard Arzneimittel GmbH & Co.KG

Aguix Gadolinium-Based Nanoparticles

Brigham and Women's Hospital

Trastuzumab

Organon and Co

Pembrolizumab

Merck & Co.

Interleukin 2

Essen Biotech

Phase 31

Nivolumab

Bristol-Myers Squibb

Approved

No programs

Analysis

Modality Breakdown

65%

Small molecule

17 of 26 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 93% of 28 pipeline programs.

Analysis

Trial Status

53

clinical trials

Completed23 · 43%

Recruiting16 · 30%

Active, not recruiting5 · 9%

Not yet recruiting3 · 6%

Unknown status2 · 4%

Terminated2 · 4%

Other2 · 4%

Clinical Trials

Trial Activity

53 trials

A Pilot Study Assessing the Safety of an Active Surveillance Approach to Local Therapy in Patients With Brain Metastases Undergoing CNS-Penetrating Systemic Therapy

Recruiting·UUniversity of California, Irvine·N/A·NCT07827001·12 enrolled

A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone

Recruiting·BBrigham and Women's Hospital·Phase 2·NCT04899908·134 enrolled

ET-NEURO: A Pilot Trial of the Exercise Together Program in Primary Brain Tumor Patient-Caregiver Dyads Incorporating Glymphatic MRI

Recruiting·OOHSU Knight Cancer Institute·Preclinical·NCT07278440·36 enrolled

Initial Safety Lead-in Followed by a Phase II Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (The Breast CMV Study)

Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT07383649·28 enrolled

Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection

Recruiting·MMayo Clinic·Preclinical·NCT06322602·30 enrolled

Artificial Intelligence-Based Prediction of Sarcopenia Risk in Intensive Care Unit Patients With Intracranial Pathology

Recruiting·TTrabzon Kanuni Education and Research Hospital·N/A·NCT07712198·100 enrolled

Neuro-Oncology Anywhere: Deploying Mayo Clinic's Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin on Cognition and Quality of Life in Patients With History of Cranial Radiation

Recruiting·MMayo Clinic·Phase 2·NCT06377696·100 enrolled

Hyperpolarized Pyruvate Imaging of Glioma: Imaging-Pathological Correlation

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03830151·13 enrolled

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Recruiting·—·Phase 1·NCT07210632·38 enrolled

Phase I/II, Open-Label Study Evaluating the Efficacy and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures

Recruiting·SStanford University·Preclinical·NCT03510208·46 enrolled

A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.

Recruiting·UUniversity College, London·Phase 1·NCT07134842·16 enrolled

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Recruiting·—·Phase 1·NCT05106296·37 enrolled

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06058988·30 enrolled

Study of How Safe and Effective Tarlatamab is in Brain Cancers

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06776250·44 enrolled

Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study

Recruiting·UUniversity Health Network, Toronto·N/A·NCT04962672·40 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)